Rebecca Sobus

Beta-adrenergic adaptation in paediatric idiopathic dilated cardiomyopathy

BACKGROUND Although the pathophysiology and treatment of adult heart failure (HF) are well studied, HF in children remains poorly understood. In adults, adrenergic receptor (AR)-mediated adaptation plays a central role in cardiac abnormalities in HF, and these patients respond well to β-blocker (BB) therapy. However, in children with HF, there is a growing body of literature suggesting a lack of efficacy of adult HF therapies. Due to these unanticipated differences in response to therapy and the paucity of data regarding the molecular adaptation of the paediatric heart, we investigated the molecular characteristics of HF in children. METHODS AND RESULTS Explanted hearts from adults and children with idiopathic dilated cardiomyopathy and non-failing controls were used in the study. Our results show that the molecular characteristics of paediatric HF are strikingly different from their adult counterparts. These differences include: (i) down-regulation of β1- and β2-AR in children, whereas β2-AR expression is maintained in adults; (ii) up-regulation of connexin43 in children, whereas down-regulation is observed in adults; (iii) no differences in phosphatase expression, whereas up-regulation is observed in adults; (iv) no decrease in the phosphorylation of phospholamban at the Ser16 or Thr17 sites in children, which are known characteristics of adult HF. CONCLUSION There is a different adaptation of β-AR and adrenergic signalling pathways in children with HF compared with adults. Our results begin to address the disparities in cardiovascular research specific to children and suggest that age-related differences in adaptation could influence the response to therapy. These findings could lead to a paradigm shift in the contemporary management of children with HF.

SEX DIFFERENCES IN CARDIOMYOCYTE CONNEXIN43 EXPRESSION

Decreases in cardiac connexin43 (Cx43) play a critical role in abnormal cell-to-cell communication and have been linked to the resistance of the female heart to arrhythmias. We therefore hypothesized that Cx43 expression would be greater in female cardiomyocytes than in male cardiomyocytes under pathologic conditions. Adult ventricular myocytes were isolated from male and female rats and treated with phenylephrine (PE), a well-established pathologic stimulus. Cx43 gene and protein expression was determined. The expression of micro-RNA-1 (miR-1), a micro-RNA known to control Cx43 protein expression in cardiomyocytes, was also determined. Cx43 mRNA and protein levels were significantly higher in the female cardiomyocytes than in the male cardiomyocytes (mRNA: 1.4-fold; Protein: 5-fold, both P < 0.05) under both basal and pathologic conditions. PE treatment increased Cx43 expression only in female cardiomyocytes. Cx43 phosphorylation, a marker of preserved Cx43 function, was also higher (P < 0.05), and The expression of miR-1 was lower (P < 0.05) in the female cardiomyocytes after PE treatment. The expression of miR-1 was unchanged by PE treatment in male cardiomyocytes. Thus, a sex difference in miR-1 may be responsible for the sex difference in Cx43 expression in cardiomyocytes under pathologic conditions. Taken together, our results demonstrate a sex difference in Cx43 expression and site-specific phosphorylation that favors cardioprotection in female cardiomyocytes.

Dysregulation of cardiolipin biosynthesis in pediatric heart failure.

Cardiolipin, a unique phospholipid in the inner mitochondrial membrane, is critical for optimal mitochondrial function. CL abnormalities have been demonstrated in the failing rodent and adult human heart. The aim of this study was to determine whether abnormalities in CL content and the CL biosynthesis and remodeling pathways are present in pediatric idiopathic dilated cardiomyopathy (IDC). A cross-sectional analysis of myocardial tissue from 119 IDC and non-failing (NF) control samples was performed. Electrospray ionizing mass spectrometry was used to measure total CL and CL species content in LV tissue. RT-PCR was employed to measure gene expression of the enzymes in the CL biosynthesis and remodeling pathways in both the adult and pediatric heart. Significantly lower total and (18:2)4CL (the beneficial species) content was demonstrated in myocardium from pediatric patients with IDC compared to NF controls. Analysis of mitochondrial gene transcripts was used to demonstrate that there is no decrease in mitochondrial content. Expression of two biosynthesis enzymes and one remodeling enzyme was significantly lower in pediatric IDC compared to NF controls. Expression of two phospholipases involved in CL degradation were also altered, one up- and one down-regulated. Except for one remodeling enzyme, these changes are unique from those in the failing adult heart. Similar to what has been seen in adults and in a rat model of IDC, total and (18:2)4CL are lower in pediatric IDC. Unique CL species profiles are seen in heart tissue from children with IDC compared to adults. Differences in CL biosynthesis and remodeling enzyme expression likely explain the differences in CL profiles observed in IDC and implicate unique age-related mechanisms of disease.

β-Adrenergic receptor antagonism in mice: a model for pediatric heart disease

Children with heart failure are treated with similar medical therapy as adults with heart failure. In contrast to adults with heart failure, these treatment regiments are not associated with improved outcomes in children. Recent studies have demonstrated age-related pathophysiological differences in the molecular mechanisms of heart failure between children and adults. There are no animal models of pediatric cardiomyopathy to allow mechanistic studies. The purpose of the current experiments was to develop a mouse model of pediatric heart disease and test whether the influence of β-adrenergic receptor (β-AR) antagonism could be modeled in this system. We hypothesized that isoproterenol treatment of young mice would provide a model system of cardiac pathology, and that nonselective β-AR blockade would provide benefit in adult, but not young, mice, similar to clinical trial data. We found that isoproterenol treatment (through osmotic minipump implantation) of young and adult mice produced similar degrees of cardiac hypertrophy and recapitulated several age-related molecular abnormalities in human heart failure, including phospholamban phosphorylation and β-AR expression. We also found that nonselective β-AR blockade effectively prevented pathological cardiac growth and collagen expression in the adult but not young mice, and that selective β1-AR blockade was effective in both young and adult isoproterenol-treated mice. In conclusion, we have developed the first model system for β-AR-mediated pediatric heart disease. Furthermore, we have generated novel data suggesting beneficial effects of selective β1-AR blockade in the pediatric heart.

Transcriptional Regulation of β2-Microglobulin Demonstrated Via a Novel Genomic and Proteomic Analysis of Percutaneously Collected Peripheral Atheroma

Atherosclerosis is a systemic disease resulting in plaque formation in multiple vascular beds. Despite progress in its prevention and treatment, the mechanisms underlying local disease development, progression, or regression remain poorly understood. To better understand the disease process and role for potential new therapeutic targets, current investigative approaches are employing expression profiling of genes and proteins.1 Many recent genomic or proteomic evaluations of atherosclerosis have focused on blood-borne markers due to the ease of access. While several serum biomarkers have demonstrated clinical utility for cardiovascular risk, such as C-reactive protein, in general, most circulating markers are not indicative of processes within plaque tissue per se.1,2 New endovascular devices may help overcome many of the current limitations in human atheroma sample collection by rapidly and relatively noninvasively harvesting endovascular plaque. The Pathway PVTM system (Pathway Medical Technologies, Inc., Kirkland, WA, USA) is a peripheral atherectomy/aspiration device that allows plaque collection during an endovascular procedure for clinically significant peripheral arterial disease (PAD). An atherectomy system capable of providing biologically intact atheroma samples will provide an invaluable research tool for determining mechanisms underlying human atherosclerosis. However, the collection of a physical sample via a percutaneous method does not guarantee that the sample is of sufficient integrity to perform high-fidelity molecular analyses to understand the mechanisms of plaque formation and adaptation. Therefore, the purpose of the current study was to determine whether plaque collected with the Pathway PVTM system was a “molecular-grade” tissue, allowing for high-fidelity genomic and proteomic analyses. We hypothesized that intact mRNA and protein could be isolated from the percutaneously collected plaque, and that gene and protein targets can be specifically and reproducibly identified. Indeed, we assayed the collected specimens for genes involved in atherosclerosis and discovered that β2-microglobulin, a protein previously demonstrated to be a plasma marker of peripheral arterial disease, is upregulated in the plaque, providing novel evidence for peripheral plaque as a source for plasma β2microglobulin.